Compare Amgen, Inc. (AMGN) vs Lithium Americas Corp (LAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Lithium Americas Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Lithium Americas Corp trades at $3.3 (market cap $1.16B). The key difference: Amgen, Inc. is far larger — about 169.1× Lithium Americas Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| AMGN | LAC | |
|---|---|---|
Market Cap | $196.12B | $1.16B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $10.05 |
52-Week Low | $271.18 | $2.55 |
Enterprise Value | $241.41B | $1.28B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lithium Americas (LAC) trades at $3.32, down 6.74% on the day, reflecting ongoing bearish pressure. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company remains unprofitable with negative net income of -$122.09 million in 2025, though it maintains a low P/B ratio of 0.87. Recent news highlights construction milestones at Thacker Pass and significant government funding interest in the rare earth sector.
LAC presents a high-risk, high-reward opportunity tied to its Thacker Pass project execution. Analyst consensus is cautiously optimistic with a $6.25 price target, but near-term risks include substantial capital needs, potential equity dilution, and persistent negative cash flow from operations. The stock's outlook hinges on successful project development and lithium market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
